Antiepileptogenesis Strategies in Neurological Disorders

Efforts to prevent the development of epilepsy following acute brain insults have focused on interrupting the complex cascade of molecular and cellular changes that underlie epileptogenesis. Key approaches under investigation include modulation of neuroinflammation, stabilisation of the blood–brain barrier and neurovascular unit, inhibition of excitatory neurotransmission, immune-based therapies and the identification of early biomarkers. Advances in understanding the roles of glial activation, complement activation and toll-like receptor signalling have opened avenues for repurposing immunomodulatory agents. Parallel work on glutamatergic receptor antagonism has demonstrated that timed interventions can delay or reduce structural reorganisation in the hippocampus, although optimal dosing and treatment windows remain under study. Complementing these targeted interventions, emerging multimodal drug candidates seek to combine modulation of several pathological pathways in a single agent. Biomarker discovery, using electrophysiological, imaging or molecular readouts, offers the prospect of stratifying at-risk individuals and guiding early therapeutic decisions. Together, these strategies hold promise for translating mechanistic insights into effective interventions that limit the onset or progression of epilepsy after injury, infection or other neurological insults.

Research from Nature Portfolio

Immune modulation with intravenous immunoglobulin (IVIg) has been shown in experimental models to attenuate acute glial activation, complement cascade engagement and blood–brain barrier disruption following status epilepticus. Post-insult administration of IVIg reduced the frequency and duration of subsequent spontaneous seizures, providing proof of principle that targeted immune intervention can modify disease trajectory. In complementary work, a combination of subtype-selective glutamate receptor antagonists administered during the latent period after an excitotoxic insult transiently prevented hippocampal granule cell dispersion and reduced early electroclinical seizure manifestations. Although the antiepileptogenic effect diminished over time, these findings underscore the critical role of glutamatergic transmission in early circuit remodelling and highlight the need for optimised dosing regimens to sustain disease-modifying benefits.

Antiepileptogenesis Strategies in Neurological Disorders publication trend

The graph below shows the total number of articles in antiepileptogenesis strategies in neurological disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Epileptogenesis: the progressive process by which a healthy brain develops a propensity for spontaneous recurrent seizures.

Neurovascular unit: the integrated ensemble of neurons, glia and vascular cells that maintains cerebral homeostasis and barrier function.

Blood–brain barrier: the selective endothelial interface that regulates molecular and cellular exchange between the blood and brain.

Glutamatergic transmission: excitatory neuronal signalling mediated by glutamate binding to its receptor subtypes.

Intravenous immunoglobulin (IVIg): a pooled preparation of human antibodies administered to modulate immune responses.

Toll-like receptor 3 (TLR3): an innate immune receptor that recognises double-stranded RNA and mediates neuroinflammatory signalling.

References

1. The Neurovascular Unit Dysfunction in the Molecular Mechanisms of Epileptogenesis and Targeted Therapy. Neuroscience Bulletin (2024).
2. Single-Target Versus Multi-Target Drugs Versus Combinations of Drugs With Multiple Targets: Preclinical and Clinical Evidence for the Treatment or Prevention of Epilepsy. Frontiers in Pharmacology (2021).
3. A combination of NMDA and AMPA receptor antagonists retards granule cell dispersion and epileptogenesis in a model of acquired epilepsy. Scientific Reports (2017).
4. Disease-modifying effect of intravenous immunoglobulin in an experimental model of epilepsy. Scientific Reports (2017).